News coverage about Pluristem Therapeutics (NASDAQ:PSTI) has been trending somewhat positive on Wednesday, Accern Sentiment reports. Accern ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Pluristem Therapeutics earned a media sentiment score of 0.08 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 45.7032287132172 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the media headlines that may have impacted Accern’s rankings:
- Pluristem Therapeutics (PSTI) and Fukushima University Report Positive Data for PLX-R18 (streetinsider.com)
- Pluristem Therapeutics reports rosy results from pre-clinical study examining treatment for radiation damage (proactiveinvestors.com)
- Pluristem and Fukushima University Report Positive Data: PLX-R18 Increases Survival Rates and Mitigates Severe Intestinal Damage after Acute Radiation Exposure (finance.yahoo.com)
- Pluristem shares jump 2% on news of positive trial of treatment for radiation damage (finance.yahoo.com)
- -$0.09 EPS Expected for Pluristem Therapeutics Inc. (PSTI) This Quarter (americanbankingnews.com)
Several equities analysts have commented on the stock. HC Wainwright set a $4.00 target price on shares of Pluristem Therapeutics and gave the company a “buy” rating in a report on Friday, May 11th. Maxim Group set a $3.00 target price on shares of Pluristem Therapeutics and gave the company a “buy” rating in a report on Monday, April 30th. ValuEngine raised shares of Pluristem Therapeutics from a “strong sell” rating to a “sell” rating in a report on Wednesday, May 2nd. MED reissued a “positive” rating on shares of Pluristem Therapeutics in a report on Monday, April 23rd. Finally, Zacks Investment Research lowered shares of Pluristem Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, March 20th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Pluristem Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $3.38.
Pluristem Therapeutics (NASDAQ:PSTI) last released its earnings results on Thursday, May 10th. The biotechnology company reported ($0.01) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.08. equities research analysts forecast that Pluristem Therapeutics will post -0.23 EPS for the current fiscal year.
About Pluristem Therapeutics
Pluristem Therapeutics Inc, together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders.
Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.